MedTrace Logo

Etanercept for the Treatment of Chronic Urticaria

NCT01030120 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2015-06-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of etanercept for patients with chronic idiopathic urticaria unresponsive to antihistamines.

Conditions

  • Chronic Idiopathic Urticaria

Interventions

DRUG

etanercept

etanercept 50mg BIW S.Q.

DRUG

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Christopher Hull, MD · University of Utah Department of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-07-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030120 on ClinicalTrials.gov